| KTE-X19 CAR T-cell therapy in relapsed or refractory mantle-cell lymphoma M Wang, J Munoz, A Goy, FL Locke, CA Jacobson, BT Hill, ... New England journal of medicine 382 (14), 1331-1342, 2020 | 1498 | 2020 |
| Axicabtagene ciloleucel in relapsed or refractory indolent non-Hodgkin lymphoma (ZUMA-5): a single-arm, multicentre, phase 2 trial CA Jacobson, JC Chavez, AR Sehgal, BM William, J Munoz, G Salles, ... The lancet oncology 23 (1), 91-103, 2022 | 440 | 2022 |
| Solid cancers after bone marrow transplantation S Bhatia, AD Louie, R Bhatia, MR O’Donnell, H Fung, A Kashyap, ... Journal of Clinical Oncology 19 (2), 464-471, 2001 | 362 | 2001 |
| Predictors of therapy-related leukemia and myelodysplasia following autologous transplantation for lymphoma: an assessment of risk factors A Krishnan, S Bhatia, ML Slovak, DA Arber, JC Niland, A Nademanee, ... Blood, The Journal of the American Society of Hematology 95 (5), 1588-1593, 2000 | 347 | 2000 |
| Late mortality in survivors of autologous hematopoietic-cell transplantation: report from the Bone Marrow Transplant Survivor Study S Bhatia, LL Robison, L Francisco, A Carter, Y Liu, M Grant, KS Baker, ... Blood 105 (11), 4215-4222, 2005 | 275 | 2005 |
| Increasing use of allogeneic hematopoietic cell transplantation in patients aged 70 years and older in the United States L Muffly, MC Pasquini, M Martens, R Brazauskas, X Zhu, K Adekola, ... Blood, The Journal of the American Society of Hematology 130 (9), 1156-1164, 2017 | 268 | 2017 |
| A phase 1/2 trial of high-dose yttrium-90-ibritumomab tiuxetan in combination with high-dose etoposide and cyclophosphamide followed by autologous stem cell transplantation in … A Nademanee, S Forman, A Molina, H Fung, D Smith, A Dagis, C Kwok, ... Blood 106 (8), 2896-2902, 2005 | 251 | 2005 |
| Multiple myeloma, version 3.2017, NCCN clinical practice guidelines in oncology SK Kumar, NS Callander, M Alsina, D Atanackovic, JS Biermann, ... Journal of the National Comprehensive Cancer Network 15 (2), 230-269, 2017 | 234 | 2017 |
| Pembrolizumab plus lenalidomide and dexamethasone for patients with treatment-naive multiple myeloma (KEYNOTE-185): a randomised, open-label, phase 3 trial SZ Usmani, F Schjesvold, A Oriol, L Karlin, M Cavo, RM Rifkin, HA Yimer, ... The Lancet Haematology 6 (9), e448-e458, 2019 | 220 | 2019 |
| Cytogenetic abnormalities in primary myelodysplastic syndrome are highly predictive of outcome after allogeneic bone marrow transplantation TJ Nevill, HC Fung, JD Shepherd, DE Horsman, SH Nantel, ... Blood, The Journal of the American Society of Hematology 92 (6), 1910-1917, 1998 | 211 | 1998 |
| Phase II trial of a transplantation regimen of yttrium-90 ibritumomab tiuxetan and high-dose chemotherapy in patients with non-Hodgkin's lymphoma A Krishnan, A Nademanee, HC Fung, AA Raubitschek, A Molina, ... Journal of clinical oncology 26 (1), 90-95, 2008 | 199 | 2008 |
| Admission of bone marrow transplant recipients to the intensive care unit: outcome, survival and prognostic factors SR Jackson, MG Tweeddale, MJ Barnett, JJ Spinelli, HJ Sutherland, ... Bone marrow transplantation 21 (7), 697-704, 1998 | 182 | 1998 |
| NCCN guidelines insights: multiple myeloma, version 3.2018 SK Kumar, NS Callander, M Alsina, D Atanackovic, JS Biermann, ... Journal of the National Comprehensive Cancer Network 16 (1), 11-20, 2018 | 156 | 2018 |
| Mesenchymal stem cells from the Wharton's jelly of umbilical cord segments provide stromal support for the maintenance of cord blood hematopoietic stem cells during long‐term … T Bakhshi, RC Zabriskie, S Bodie, S Kidd, S Ramin, LA Paganessi, ... Transfusion 48 (12), 2638-2644, 2008 | 151 | 2008 |
| A long-term follow-up report on allogeneic stem cell transplantation for patients with primary refractory acute myelogenous leukemia: impact of cytogenetic characteristics on … HC Fung, A Stein, ML Slovak, MR O’donnell, DS Snyder, S Cohen, ... Biology of Blood and Marrow Transplantation 9 (12), 766-771, 2003 | 148 | 2003 |
| Primary analysis of Zuma-5: a phase 2 study of axicabtagene ciloleucel (Axi-Cel) in patients with relapsed/refractory (R/R) indolent non-Hodgkin lymphoma (iNHL) C Jacobson, JC Chavez, AR Sehgal, BM William, J Munoz, G Salles, ... Blood 136, 40-41, 2020 | 145 | 2020 |
| Long-term follow-up of 23 patients with Philadelphia chromosome-positive acute lymphoblastic leukemia treated with allogeneic bone marrow transplant in first complete remission DS Snyder, AP Nademanee, MR O’donnell, PM Parker, AS Stein, ... Leukemia 13 (12), 2053-2058, 1999 | 141 | 1999 |
| Lymphoproliferative disorders following allogeneic bone marrow transplantation: the Vancouver experience INM Micallef, M Chhanabhai, RD Gascoyne, JD Shepherd, HC Fung, ... Bone marrow transplantation 22 (10), 981-987, 1998 | 132 | 1998 |
| Results of high-dose therapy and autologous bone marrow/stem cell transplantation during remission in poor-risk intermediate-and high-grade lymphoma: international index high … A Nademanee, A Molina, MR O'Donnell, A Dagis, DS Snyder, P Parker, ... Blood, The Journal of the American Society of Hematology 90 (10), 3844-3852, 1997 | 122 | 1997 |
| Phase II study of the PD-1 inhibitor pembrolizumab for the treatment of relapsed or refractory mature T-cell lymphoma SK Barta, J Zain, AW MacFarlane IV, SM Smith, J Ruan, HC Fung, CR Tan, ... Clinical Lymphoma Myeloma and Leukemia 19 (6), 356-364. e3, 2019 | 111 | 2019 |
Arturo Molina, MD, MS, FACPChief Medical Officer, Sutro Biopharma在 sutrobio.com 的电子邮件经过验证
